ResMed, Inc.

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 21:00:02 08/12/2025 GMT			5-day change	1st Jan Change
250.04 ^USD	-2.54%		+0.67%	+9.34%

12-08	ResMed Receives FDA Clearance for AI-Powered Device to Personalize Sleep Apnea Therapy	MT
12-04	Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing	MT

Wells Fargo Adjusts ResMed Price Target to $265 From $280

Published on 10/31/2025 at 03:32 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about ResMed, Inc.

12-08	ResMed Receives FDA Clearance for AI-Powered Device to Personalize Sleep Apnea Therapy	MT
12-04	Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing	MT
12-02	LivaNova PLC Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea, Effective December 1, 2025	CI
11-25	ResMed Inc. Announces Not Seek Re-Election of Richard Sulpizio to the Board of Directors, Effective November 19, 2025	CI
11-25	UK financial sector makes slow progress on preparations for new settlement system	RE
11-11	ResMed Insider Sold Shares Worth $2,000,773, According to a Recent SEC Filing	MT
11-05	ResMed CFO Sells Shares	MT
11-05	ResMed CFO Buys, Sells Shares	MT
11-04	Resmed Insider Sold Shares Worth $742,620, According to a Recent SEC Filing	MT
11-03	ResMed CFO Sells Shares	MT
11-03	ASX Biggest Losers	MT
11-03	ASX Midday Sector Update: Information Technology Stocks Rise, Healthcare Down	MT
10-31	Baird Adjusts Price Target on ResMed to $300 From $320	MT
10-31	Jefferies & Co Adjusts ResMed Price Target to $285 From $290	MT
10-31	Wells Fargo Adjusts ResMed Price Target to $265 From $280	MT
10-31	Wolfe Research Adjusts ResMed Price Target to $225 From $215	MT
10-31	Morgan Stanley Adjusts ResMed Price Target to $305 From $304	MT
10-31	Mizuho Adjusts Price Target on ResMed to $300 From $310	MT
10-31	KeyBanc Adjusts Price Target on ResMed to $299 From $298	MT
10-31	RBC Lifts Price Target on ResMed to $303 From $300, Keeps Outperform Rating	MT
10-31	Morgan Stanley Lifts Price Target on ResMed to $305 From $304, Keeps Overweight Rating	MT
10-31	Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014.	CI
10-31	ResMed's innovation-driven success and prospects
10-31	Australian Shares Flat; ANZ Group Flags Net After-Tax Charge of Over AU$1 Billion in Fiscal H2	MT
10-30	ASX Preview: Australian Shares Set to Rise After US-China Trade Truce; ResMed Posts Higher Fiscal Q1 Non-GAAP Earnings, Revenue	MT

ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (51.8%); - masks (35.7%); - software as a service (12.5%): residential care management software solutions. At the end of June 2025, the group had 8 production sites located in the United States (3), Australia, China, Singapore, Malaysia and France. The United States accounts for 63.8% of net sales.

Employees

10,600

Sector

Advanced Medical Equipment & Technology

Calendar

01-21 - Q2 2026 Earnings Release (Projected)

More about the company